Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07402876 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
A Phase 3 study of Primary Vitreoretinal Lymphoma, sponsored by Aldeyra Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07402876 is a Phase 3 study of Primary Vitreoretinal Lymphoma that is actively recruiting participants, run by Aldeyra Therapeutics. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07402876, a Phase 3 study of Primary Vitreoretinal Lymphoma, is actively recruiting participants, sponsored by Aldeyra Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
Conditions Studied
Interventions
- DRUG ICM ADX-2191 injection
- DRUG Monthly ADX-2191 injection
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07402876
The ClinicalTrials.gov registry entry for NCT07402876 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Vitreoretinal Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which ICM ADX-2191 injection is the first listed.
NCT07402876 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07402876 about?
NCT07402876 is a clinical study titled "A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma". A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
What is the current status of trial NCT07402876?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2026-02. Estimated completion is 2026-12.
What conditions does trial NCT07402876 study?
This clinical trial studies the following conditions: Primary Vitreoretinal Lymphoma.
What interventions are being tested in trial NCT07402876?
The interventions under investigation include: ICM ADX-2191 injection (DRUG), Monthly ADX-2191 injection (DRUG).
Who is sponsoring clinical trial NCT07402876?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07402876 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.